复发/难治霍奇金淋巴瘤免疫治疗进展及思考
Advances and Reflections on Immunotherapy in Relapsed/Refractory Hodgkin Lymphoma
DOI: 10.12677/acm.2026.1652005, PDF,    科研立项经费支持
作者: 宋 懿：上海交通大学医学院附属瑞金医院血液科，上海血液学研究所，医学基因组学国家重点实验室，国家转化医学研究中心(上海)，上海；虞文嫣, 糜坚青*：上海交通大学医学院附属瑞金医院血液科，上海血液学研究所，医学基因组学国家重点实验室，国家转化医学研究中心(上海)，上海；上海市血液病基因编辑与细胞免疫治疗重点实验室，上海
关键词: 霍奇金淋巴瘤；复发；难治；免疫治疗；Hodgkin Lymphoma； Relapsed； Refractory； Immunotherapy
摘要: 霍奇金淋巴瘤(Hodgkin lymphoma, HL)是目前可能实现大部分治愈的血液肿瘤，临床上仍有10%~15%的早期患者出现难治及15%~30%的患者晚期复发，因此此类复发/难治性霍奇金淋巴瘤(relapsed/refractory Hodgkin lymphoma, R/R HL)的治疗始终是临床一大挑战。尽管现阶段二线挽救治疗方案众多，但其最佳方案尚未明确。近十几年来维布妥昔单抗(brentuximab vedotin, BV)与程序性死亡受体-1抑制剂(programmed death-1 inhibitor, PD-1i)两类新型药物被纳入挽救方案，使得自体造血干细胞移植(autologous stem cell transplantation, ASCT)的完全缓解率(complete response rate, CRR)得以提升。当前以嵌合抗原受体T细胞疗法(chimeric antigen receptor T-cell therapy, CAR-T)及双特异性抗体(bispecific antibody, BsAb)等为代表的新兴免疫疗法，逐步在后续的治疗中展现出重要的价值。本文旨在全面描述R/R HL的挽救治疗现状和新兴免疫治疗方法，并对未来R/R HL免疫治疗的发展趋势予以总结及思考。
Abstract: Hodgkin lymphoma (HL) is currently one of the hematologic malignancies with a high potential for cure. Nevertheless, approximately 10%~15% of patients with early-stage disease and 15%~30% of patients with advanced-stage disease still experience refractory disease or relapse. Therefore, the management of relapsed/refractory Hodgkin lymphoma (R/R HL) remains a major clinical challenge. Although a variety of second-line salvage regimens are available, the optimal approach has not been definitively established. Over the past decade, the introduction of two novel agents—brentuximab vedotin (BV) and programmed death-1 inhibitors (PD-1i) into salvage therapy has improved the complete response rate (CRR) of autologous stem cell transplantation (ASCT). Moreover, emerging immunotherapeutic approaches such as chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAb) are increasingly demonstrating important value in later lines of treatment. This review aims to comprehensively describe the current status of salvage therapy for R/R HL, to discuss novel immunotherapeutic methods, and to summarize and reflect on future directions in the immunotherapy of R/R HL.
文章引用：宋懿, 虞文嫣, 糜坚青. 复发/难治霍奇金淋巴瘤免疫治疗进展及思考[J]. 临床医学进展, 2026, 16(5): 1989-1999. https://doi.org/10.12677/acm.2026.1652005

参考文献

[1] Ansell, S.M. (2024) Hodgkin Lymphoma: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal of Hematology, 99, 2367-2378. [Google Scholar] [CrossRef] [PubMed]
[2] Moskowitz, A.J., Shah, G., Schöder, H., Ganesan, N., Drill, E., Hancock, H., et al. (2021) Phase II Trial of Pembrolizumab plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 39, 3109-3117. [Google Scholar] [CrossRef] [PubMed]
[3] Gokarn, A., Reddy, L., Hiregoudar, S., Poojary, M., Parab, S., Punatar, S., et al. (2025) A Comparison of Mobilization Regimens Used in Hodgkin Lymphoma and Factors That Influence Peripheral Blood Stem Cell Mobilization. Cytotherapy, 27, 619-625. [Google Scholar] [CrossRef] [PubMed]
[4] Grover, N.S., Dittus, C., Thakkar, A. and Beaven, A.W. (2023) The Optimal Management of Relapsed and Refractory Hodgkin Lymphoma: Post-Brentuximab and Checkpoint Inhibitor Failure. Hematology, 2023, 510-518. [Google Scholar] [CrossRef] [PubMed]
[5] Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., et al. (2012) Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin’s Lymphoma. Journal of Clinical Oncology, 30, 2183-2189. [Google Scholar] [CrossRef] [PubMed]
[6] Martínez, C., Khvedelidze, I., Fekom, M., Deau Fischer, B., Marouf, A., Ghesquières, H., et al. (2025) Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) as Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, Fil, Lysa, and Turkish Lymphoma Group. Bone Marrow Transplantation, 60, 879-887. [Google Scholar] [CrossRef] [PubMed]
[7] Eyre, T.A., Phillips, E.H., Linton, K.M., Arumainathan, A., Kassam, S., Gibb, A., et al. (2017) Results of a Multicentre UK‐Wide Retrospective Study Evaluating the Efficacy of Brentuximab Vedotin in Relapsed, Refractory Classical Hodgkin Lymphoma in the Transplant Naive Setting. British Journal of Haematology, 179, 471-479. [Google Scholar] [CrossRef] [PubMed]
[8] LaCasce, A.S., Bociek, R.G., Sawas, A., Caimi, P., Agura, E., Matous, J., et al. (2020) Three‐Year Outcomes with Brentuximab Vedotin plus Bendamustine as First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. British Journal of Haematology, 189, E86-E90. [Google Scholar] [CrossRef] [PubMed]
[9] Stamatoullas, A., Ghesquières, H., Feugier, P., André, M., Le Bras, F., Gac, A., et al. (2022) Final Results of Brentuximab Vedotin Combined with Ifosfamide-Carboplatin-Etoposide in First Refractory/Relapsed Hodgkin Lymphoma: A Lymphoma Study Association Phase I/II Study. Leukemia & Lymphoma, 63, 3063-3071. [Google Scholar] [CrossRef] [PubMed]
[10] Kersten, M.J., Driessen, J., Zijlstra, J.M., et al. (2020) Combining Brentuximab Vedotin with Dexamethasone, High-Dose Cytarabine and Cisplatin as Salvage Treatment in Relapsed or Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant Brave Study. Haematologica, 106, 1129-1137. [Google Scholar] [CrossRef] [PubMed]
[11] Garcia-Sanz, R., Sureda, A., de la Cruz, F., Canales, M., Gonzalez, A.P., Pinana, J.L., et al. (2019) Brentuximab Vedotin and ESHAP Is Highly Effective as Second-Line Therapy for Hodgkin Lymphoma Patients (Long-Term Results of a Trial by the Spanish GELTAMO Group). Annals of Oncology, 30, 612-620. [Google Scholar] [CrossRef] [PubMed]
[12] Caro, J. and Diefenbach, C. (2021) New Approaches to Managing Relapsed/Refractory Hodgkin Lymphoma: The Role of Checkpoint Inhibitors and Beyond. Expert Review of Hematology, 14, 741-750. [Google Scholar] [CrossRef] [PubMed]
[13] Halahleh, K., Al Sawajneh, S., Saleh, Y., Shahin, O., Abufara, A., Ma’koseh, M., et al. (2022) Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma after Autologous Transplant and in Transplant-Naïve Patients. Clinical Lymphoma Myeloma and Leukemia, 22, 589-595. [Google Scholar] [CrossRef] [PubMed]
[14] Song, Y., Gao, Q., Zhang, H., Fan, L., Zhou, J., Zou, D., et al. (2022) Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-Up and Correlative Biomarker Analysis. Clinical Cancer Research, 28, 1147-1156. [Google Scholar] [CrossRef] [PubMed]
[15] Shi, Y., Su, H., Song, Y., Jiang, W., Sun, X., Qian, W., et al. (2019) Safety and Activity of Sintilimab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial. The Lancet Haematology, 6, e12-e19. [Google Scholar] [CrossRef] [PubMed]
[16] Mei, M., Palmer, J., Lee, H.J., Isufi, I., Chen, R., Tsai, N., et al. (2025) Nivolumab Plus Ifosfamide, Carboplatin, and Etoposide Are a Highly Effective First Salvage Regimen in High‐Risk Relapsed/Refractory Hodgkin Lymphoma. HemaSphere, 9, E70126. [Google Scholar] [CrossRef] [PubMed]
[17] Advani, R.H., Moskowitz, A.J., Bartlett, N.L., Vose, J.M., Ramchandren, R., Feldman, T.A., et al. (2021) Brentuximab Vedotin in Combination with Nivolumab in Relapsed or Refractory Hodgkin Lymphoma: 3-Year Study Results. Blood, 138, 427-438. [Google Scholar] [CrossRef] [PubMed]
[18] Cheson, B.D., Bartlett, N.L., Knopf, B., Lee, H.J., Advani, R.H., Christian, B., et al. (2025) Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-Term Results. Blood Advances, 9, 3750-3753. [Google Scholar] [CrossRef] [PubMed]
[19] Kuruvilla, J., Modi, D., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N.A., et al. (2025) Pembrolizumab in Relapsed or Refractory Hodgkin Lymphoma: A Post Hoc Analysis of Keynote-204 by Prior Lines of Therapy. Leukemia & Lymphoma, 66, 1710-1719. [Google Scholar] [CrossRef] [PubMed]
[20] Desai, S.H., Spinner, M.A., David, K., Bachanova, V., Goyal, G., Kahl, B., et al. (2023) Checkpoint Inhibitor‐based Salvage Regimens Prior to Autologous Stem Cell Transplant Improve Event‐Free Survival in Relapsed/Refractory Classic Hodgkin Lymphoma. American Journal of Hematology, 98, 464-471. [Google Scholar] [CrossRef] [PubMed]
[21] Georgoulis, V., Papoudou-Bai, A., Makis, A., Kanavaros, P. and Hatzimichael, E. (2023) Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications. Biology, 12, Article 862. [Google Scholar] [CrossRef] [PubMed]
[22] Voorhees, T.J., McLaughlin, E.M., Torka, P., Florindez, J., Kim, N.H., Moyo, T.K., et al. (2025) Outcomes in Patients with Classic Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-Pd-1 Therapy: A Real World Analysis from 15 U.S. Academic Centers. Blood Cancer Journal, 15, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, S., Gu, C., Huang, L., Wu, H., Shi, J., Zhang, Z., et al. (2022) The Third-Generation Anti-Cd30 CAR T-Cells Specifically Homing to the Tumor and Mediating Powerful Antitumor Activity. Scientific Reports, 12, Article No. 10488. [Google Scholar] [CrossRef] [PubMed]
[24] Ramos, C.A., Grover, N.S., Beaven, A.W., Lulla, P.D., Wu, M., Ivanova, A., et al. (2020) Anti-Cd30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. Journal of Clinical Oncology, 38, 3794-3804. [Google Scholar] [CrossRef] [PubMed]
[25] Meng, F., Xiang, M., Liu, Y. and Zeng, D. (2025) Safety and Efficacy of Anti-Cd30 CAR-T Cell Therapy in Relapsed/Refractory Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis. BMC Cancer, 25, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[26] Tschernia, N.P., Heiling, H., Deal, A.M., Cheng, C., Babinec, C., Gonzalez, M., et al. (2023) Patient-Reported Outcomes in Cd30-Directed CAR-T Cells against Relapsed/Refractory CD30+ Lymphomas. Journal for ImmunoTherapy of Cancer, 11, e006959. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, S. and van den Brink, M.R.M. (2024) Allogeneic “Off-the-Shelf” CAR T Cells: Challenges and Advances. Best Practice & Research Clinical Haematology, 37, Article 101566. [Google Scholar] [CrossRef] [PubMed]
[28] Quach, D.H., Ganesh, H.R., Briones, Y.D., Nouraee, N., Ma, A., Hadidi, Y.F., et al. (2024) Rejection Resistant Cd30.Car-Modified Epstein-Barr Virus-Specific T Cells as an Off-the-Shelf Platform for CD30+ Lymphoma. Molecular Therapy Oncology, 32, Article 200814. [Google Scholar] [CrossRef] [PubMed]
[29] Muhsen, I.N., Hill, L.C. and Ramos, C.A. (2023) Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematology/Oncology Clinics of North America, 37, 1107-1124. [Google Scholar] [CrossRef] [PubMed]
[30] Park, C.H., Cho, H. and Kim, S. (2025) Treatment of Older Patients with Hodgkin Lymphoma. Blood Research, 60, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[31] Meier, J.A., Savoldo, B. and Grover, N.S. (2022) The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma. Journal of Personalized Medicine, 12, Article 197. [Google Scholar] [CrossRef] [PubMed]
[32] Younes, A., Sureda, A., Ben-Yehuda, D., Zinzani, P.L., Ong, T., Prince, H.M., et al. (2012) Panobinostat in Patients with Relapsed/Refractory Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Results of a Phase II Study. Journal of Clinical Oncology, 30, 2197-2203. [Google Scholar] [CrossRef] [PubMed]
[33] Johnston, P.B., Pinter-Brown, L.C., Warsi, G., White, K. and Ramchandren, R. (2018) Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma. Experimental Hematology & Oncology, 7, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, H., Yan, Y., Yi, S. and Sun, Q. (2025) Advancements in Targeting CD30 for Lymphoma Therapy: A Historical Perspective and Future Directions. Expert Review of Hematology, 18, 373-386. [Google Scholar] [CrossRef] [PubMed]
[35] Spinner, M.A. and Advani, R.H. (2024) Emerging Immunotherapies in the Hodgkin Lymphoma Armamentarium. Expert Opinion on Emerging Drugs, 29, 263-275. [Google Scholar] [CrossRef] [PubMed]
[36] Epperla, N. and Hamadani, M. (2021) A New Target for Hodgkin Lymphoma-Camidanlumab Tesirine. Current Hematologic Malignancy Reports, 16, 19-24. [Google Scholar] [CrossRef] [PubMed]
[37] Wagner, C.B., Boucher, K., Nedved, A., Micallef, I.N., Desai, S., Hatic, H., et al. (2023) Effect of Cumulative Dose of Brentuximab Vedotin Maintenance in Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Stem Cell Transplant: An Analysis of Real-World Outcomes. Haematologica, 108, 3025-3032. [Google Scholar] [CrossRef] [PubMed]
[38] Armand, P., Zinzani, P.L., Lee, H.J., Johnson, N.A., Brice, P., Radford, J., et al. (2023) Five-Year Follow-Up of KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 142, 878-886. [Google Scholar] [CrossRef] [PubMed]
[39] Varma, G. and Diefenbach, C. (2024) The Role of Autologous Stem-Cell Transplantation in Classical Hodgkin Lymphoma in the Modern Era. Seminars in Hematology, 61, 253-262. [Google Scholar] [CrossRef] [PubMed]
[40] Ravindra, A. and Mou, E. (2025) Incorporating Novel Therapies into the Treatment of Older Patients with Classic Hodgkin Lymphoma. Expert Review of Hematology, 18, 735-751. [Google Scholar] [CrossRef] [PubMed]
[41] Takiar, R. and Karimi, Y. (2022) Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose? Cancers, 14, Article 3526. [Google Scholar] [CrossRef] [PubMed]
[42] Abeyakoon, C. and Kuruvilla, J. (2024) Optimizing Salvage Therapy for Hodgkin Lymphoma: Progress and Future Challenges. Expert Review of Hematology, 17, 467-478. [Google Scholar] [CrossRef] [PubMed]
[43] Wang, C., Pan, Y., Liu, Y., Guo, B., Shi, J., Rong, G., et al. (2023) Long‐Term Complete Remission and Peripheral Biomarkers in Hodgkin Lymphoma Patients after Decitabine‐plus‐Camrelizumab Epi‐Immunotherapy and Treatment Cessation. MedComm, 4, E428. [Google Scholar] [CrossRef] [PubMed]
[44] Miljak, A., Pavlović, A., Benzon, B., Čutura, L.V., Galušić, D., Vujčić, M., et al. (2025) High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma. International Journal of Molecular Sciences, 26, Article 5592. [Google Scholar] [CrossRef] [PubMed]
[45] Calabretta, E., di Trani, M., Corrado, F., Sollini, M., Cristaldi, V., Marino, F., et al. (2024) Baseline Circulating Tumour DNA and Interim pet Predict Response in Relapsed/Refractory Classical Hodgkin Lymphoma. British Journal of Haematology, 204, 514-524. [Google Scholar] [CrossRef] [PubMed]
[46] Eisazadeh, R. and Mirshahvalad, S.A. (2022) 18F-FDG PET/CT Prognostic Role in Predicting Response to Salvage Therapy in Relapsed/Refractory Hodgkin’s Lymphoma. Clinical Imaging, 92, 25-31. [Google Scholar] [CrossRef] [PubMed]

为你推荐